Therapeutic antibodies have been used since the end of nineteenth century, but their use is progressively increased and recently, with the availability of monoclonal antibodies, they are successfully employed in a large disease spectrum, which transversally covers different fields of medicine. Hyperimmune polyclonal immune globulin has been used against infectious diseases, in a period in which anti-microbial drugs were not yet available, and it still maintains a relevant place in prophylaxis/therapy. Although immune globulin should be considered life-saving as replacement therapy in humoral immunodeficiencies, its place in the immune-modulating treatment is not usually first-choice, but it should be considered as support to standard approved treatments. Despite therapeutic monoclonal antibodies have been lastly introduced in therapy, their extreme potentiality is reflected by the large number of approved molecules, addressed toward different immunological targets and able to heavily influence the prognosis and quality of life of a wide range of different diseases.

The expanding role of therapeutic antibodies / Simonetta, Salemi; Milica, Markovic; Gabriella, Martini; D'Amelio, Raffaele. - In: INTERNATIONAL REVIEWS OF IMMUNOLOGY. - ISSN 0883-0185. - STAMPA. - 34:3(2015), pp. 202-264. [10.3109/08830185.2013.863304]

The expanding role of therapeutic antibodies

D'AMELIO, Raffaele
2015

Abstract

Therapeutic antibodies have been used since the end of nineteenth century, but their use is progressively increased and recently, with the availability of monoclonal antibodies, they are successfully employed in a large disease spectrum, which transversally covers different fields of medicine. Hyperimmune polyclonal immune globulin has been used against infectious diseases, in a period in which anti-microbial drugs were not yet available, and it still maintains a relevant place in prophylaxis/therapy. Although immune globulin should be considered life-saving as replacement therapy in humoral immunodeficiencies, its place in the immune-modulating treatment is not usually first-choice, but it should be considered as support to standard approved treatments. Despite therapeutic monoclonal antibodies have been lastly introduced in therapy, their extreme potentiality is reflected by the large number of approved molecules, addressed toward different immunological targets and able to heavily influence the prognosis and quality of life of a wide range of different diseases.
2015
intravenous immune globulin; passive immunization; subcutaneous immune globulin; therapeutic monoclonal antibodies
01 Pubblicazione su rivista::01a Articolo in rivista
The expanding role of therapeutic antibodies / Simonetta, Salemi; Milica, Markovic; Gabriella, Martini; D'Amelio, Raffaele. - In: INTERNATIONAL REVIEWS OF IMMUNOLOGY. - ISSN 0883-0185. - STAMPA. - 34:3(2015), pp. 202-264. [10.3109/08830185.2013.863304]
File allegati a questo prodotto
File Dimensione Formato  
Salemi_Expanding_2015.pdf

solo utenti autorizzati

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 415.03 kB
Formato Adobe PDF
415.03 kB Adobe PDF   Contatta l'autore
Salemi_Expanding_2015.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 418.64 kB
Formato Adobe PDF
418.64 kB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/562787
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 22
  • ???jsp.display-item.citation.isi??? 21
social impact